<DOC>
	<DOCNO>NCT00431561</DOCNO>
	<brief_summary>In multinational dose find Phase IIb study efficacy safety two dos AP 12009 compare standard chemotherapy ( temozolomide PCV ) investigate adult patient confirm recurrent high-grade glioma .</brief_summary>
	<brief_title>Phase IIb Clinical Trial With TGF-Î²2 Antisense Compound AP 12009 Recurrent Refractory High-grade Glioma</brief_title>
	<detailed_description>The purpose study compare safety efficacy two dos AP 12009 standard chemotherapy adult patient recurrent high-grade glioma ( anaplastic astrocytoma [ AA ] , WHO grade III ; glioblastoma [ GBM ] , WHO grade IV ) . AP 12009 phosphorothioate antisense oligodeoxynucleotide specific mRNA human transform growth factor-beta2 ( TGF-beta2 ) . The growth factor TGF-beta play key role malignant progression various tumor induce proliferation , invasion , metastasis , angiogenesis escape immunosurveillance . It show number tumor type degree TGF-beta production strongly correlate tumor grade stage . In patient high-grade glioma , TGF-beta2 overexpression associate disease stage , clinical prognosis immunodeficient state patient .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Trabedersen</mesh_term>
	<criteria>Histopathologically confirm diagnosis recurrent refractory highgrade glioma ( anaplastic astrocytoma , WHO grade III ; glioblastoma , WHO grade IV ) Supratentorial localization No two chemotherapy regimen include radiochemotherapy since primary diagnosis Eligible either TMZ PCV treatment Recovery acute toxicity cause previous therapy Adequate organ function KPS least 70 % Tumor surgery within 2 week prior study entry Radiation therapy within 8 week prior study entry Chemotherapy within 4 week prior study entry ( nitrosureas : 6 week ) No 3 mg/day dexamethasone ( equivalent ) baseline Prior TGFbeta target therapy tumor vaccination Baseline MRI show mass effect Known active infection HIV , HBV , HCV ; acute viral , bacterial , fungal infection Significant psychiatric disorders/legal incapacity limited legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>Antisense</keyword>
	<keyword>Cancer</keyword>
	<keyword>Transforming growth factor beta2 ( TGF-beta2 )</keyword>
	<keyword>Targeted therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Central nervous system ( CNS )</keyword>
	<keyword>Convection-enhanced delivery ( CED ) / microperfusion</keyword>
	<keyword>Locoregional application</keyword>
</DOC>